Skip to content
Lower risk Drug recall · FDA · Published May 9, 2023

B. Braun Medical Heparin Injection Recall: Subpotent Risk

B. Braun Medical recalls heparin sodium injections with low anti-factor IIa potency. This may cause ineffective blood clotting. Affected products have specific lot numbers and expiration dates.

🇺🇸 FDA recall #D-0579-2023DrugB. Braun Medical ›
Take action

Contact the company

Recalling firmB. Braun Medical Inc2525 Mcgaw Ave · Irvine, CA 92614-5841
✎ GovInfoNow plain-language explainer

B. Braun Medical is recalling heparin sodium injections that may have low anti-factor IIa potency. This could lead to ineffective blood clotting if used in medical treatments. Read more at govinfonow.com/recall/33493-b-braun-medical-heparin-injection-recall-subpotent-risk.

Source Summary by GovInfoNow · govinfonow.com/recall/33493-b-braun-medical-heparin-injection-recall-subpotent-risk · Updated September 23, 2026 · FDA enforcement record: FDA #D-0579-2023

Cite this page

“B. Braun Medical Heparin Injection Recall: Subpotent Risk.” GovInfoNow, updated September 23, 2026. https://govinfonow.com/recall/33493-b-braun-medical-heparin-injection-recall-subpotent-risk. Based on FDA recall #D-0579-2023 (https://api.fda.gov/drug/enforcement.json?search=recall_number:%22D-0579-2023%22&limit=1).

B. Braun Medical Inc. recalled Heparin Sodium injection nationwide on May 9, 2023, due to subpotent low anti-factor IIa potency, the FDA said. The voluntary Class II recall affects 1,380 units distributed across the United States.

How to tell if you have it

  • Brand: B. Braun Medical
  • Product: Heparin Sodium, 25,000 USP units per 250mL, (100 USP units per mL) in 5% Dextrose injection, 250 ml Excel Container
  • NDC: 0264-9587-20
  • Lot Number: J1P154N
  • Expiration Date: 31 May, 2023

The hazard

The recalled Heparin Sodium injection presents a subpotent hazard characterized by low anti-factor IIa potency. The FDA classified this as a Class II recall.

Context

GovInfoNow's records show B Braun Medical Inc has issued 66 other recalls since October 15, 2013. Recent similar product recalls include Somerset Therapeutics Cisatracurium Besylate Injection (November 26, 2025), Lupin Ganirelix Acetate Injection (November 13, 2025), and Par Health Buprenorphine Injection (June 12, 2026).

How to tell if you have this one

Check for the product name: Heparin Sodium, 25,000 USP units per 250mL in 5% Dextrose injection. Look for the lot number J1P154N and expiration date of May 31, 2023.

  • Brand
    B. Braun Medical
  • Category
    Drug
Based on the official FDA remedy

What to do — step by step

  1. Check Product Details

    Verify the lot number and expiration date on the product label.

Where it went and when

Where it was distributed

Distributed nationwide.

Alaska: yesAKMaine: yesMEVermont: yesVTNew Hampshire: yesNHWashington: yesWAIdaho: yesIDMontana: yesMTNorth Dakota: yesNDMinnesota: yesMNIllinois: yesILWisconsin: yesWIMichigan: yesMINew York: yesNYRhode Island: yesRIMassachusetts: yesMAOregon: yesORNevada: yesNVWyoming: yesWYSouth Dakota: yesSDIowa: yesIAIndiana: yesINOhio: yesOHPennsylvania: yesPANew Jersey: yesNJConnecticut: yesCTCalifornia: yesCAUtah: yesUTColorado: yesCONebraska: yesNEMissouri: yesMOKentucky: yesKYWest Virginia: yesWVVirginia: yesVAMaryland: yesMDDelaware: yesDEArizona: yesAZNew Mexico: yesNMKansas: yesKSArkansas: yesARTennessee: yesTNNorth Carolina: yesNCSouth Carolina: yesSCDistrict of Columbia: yesDCOklahoma: yesOKLouisiana: yesLAMississippi: yesMSAlabama: yesALGeorgia: yesGAHawaii: yesHITexas: yesTXFlorida: yesFL

FDA distribution: “Nationwide in the USA” States read from FDA’s own wording; “not listed” means the notice does not name it.

Distributed nationwide.

Recall timeline

FDA terminated this recall 10 months after the firm started it.

1. Firm started the recall: May 9, 202312. FDA classified it Class II: May 16, 202323. Published in FDA’s Enforcement Report: May 24, 202334. FDA terminated the recall: Mar 14, 2024420232024
  1. Firm started the recall
  2. FDA classified it Class II
  3. Published in FDA’s Enforcement Report
  4. FDA terminated the recall

Dates from the agency record only; steps without a date are left out.

Similar recalls

Latest drug recalls

Keep exploring

Where this comes from

The facts (hazard, remedy, dates, manufacturer) are pulled from the official FDA recall record. The plain-language summary and step-by-step checklist are written by GovInfoNow to make the official notice easier to act on — they don’t replace it.

  • Official source: FDA Recall #D-0579-2023 (May 9, 2023) — FDA publishes no per-recall page; this is the official machine-readable enforcement record. Search FDA recalls for D-0579-2023 to see it in context.
  • Plain-language summary written by qwen3:4b on September 23, 2026, from the official record above. Not reviewed by a person — if it conflicts with the FDA notice, the notice is correct. Report an error on this page.
  • GovInfoNow is an independent service and is not a government agency. We republish official FDA recall data; we don’t issue, amend or administer recalls.
GovInfoNow is an independent guide. We are not FDA or any government agency. Always confirm details with the official recall.Data: CPSC · FDA · NHTSA · USDA